June 2015

New Product - Keytruda

Keytruda (pembrolizumab) is a selective humanized monoclonal antibody designed to block the interaction between PD‑1 and its ligands, PD‑L1 and PD-L2. Pembrolizumab is an IgG4 kappa immunoglobulin. By inhibiting the PD‑1 receptor from binding to its ligands, Keytruda reactivates tumour-specific cytotoxic T lymphocytes in the tumour microenvironment and reactivates anti‑tumour immunity. Keytruda is indicated as monotherapy for the treatment of unresectable or metastatic melanoma in adults. Keyruda is available as a 50 mg powder for infusion in single use vials of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au